Minster: GlaxoSmithKline extends rights to tonabersat

By Lisa Kerner

Charlotte, N.C., Sept. 7 - Minster Pharmaceuticals plc said GlaxoSmithKline extended its development and commercialization rights to tonabersat to include epilepsy, pain and other neurological conditions.

"Our current focus with tonabersat is on the prevention of migraine and it will take some time to define a strategy for progressing the molecule into other indications," Minster's chief executive officer Paul Sharpe said in a company news release.

Minster is a London-based drug development company specializing in neurological and psychiatric disorders.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.